Radiopharm Theranostics (RADX) Cash & Equivalents (2024 - 2025)
Radiopharm Theranostics (RADX) reported Cash & Equivalents of $11.9 million for Q2 2025, up 54.29% year-over-year from $7.7 million in Q2 2024, and up 54.29% quarter-over-quarter from $7.7 million in Q2 2024.
Radiopharm Theranostics (RADX) Cash & Equivalents (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has 2 years of Cash & Equivalents data on file, last reported at $11.9 million in Q2 2025.
- Cash & Equivalents for Q2 2025 came in at $11.9 million, up 54.29% year-over-year; the trailing twelve-month figure through Jun 2025 was $11.9 million (up 54.29% YoY), and the FY2025 annual result was $29.1 million, up 56.75% from the prior year.
- Cash & Equivalents advanced to $11.9 million in Q2 2025 per RADX's latest filing, from $7.7 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $11.9 million in Q2 2025 and troughed at $7.7 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Radiopharm Theranostics | 5.82 Bn | 5.81 Bn | - | 11.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 11.90 Mn |
| Jun 30, 2024 | 7.71 Mn |